Table 1.
Patient characteristics according to the presence of sarcopenia
| All patients (n = 203) | Sarcopenia absent (n = 126, 62.1%) | Sarcopenia present (n = 77, 37.9%) | P‐value | |
|---|---|---|---|---|
| TPMT (mm/m), mean ± SD | 12 ± 3.4 | 13.7 ± 2.9 | 9.2 ± 2.1 | <.001 |
| Age (years), mean ± SD | 55 ± 11 | 55 ± 10.8 | 54.5 ± 11.5 | .613 |
| Men (n, %) | 138 (68%) | 76 (60.3%) | 62 (80.5%) | .003 |
| Women (n, %) | 65 (32) | 50 (39.7) | 15 (19.5) | |
| Aetiology, n (%) | ||||
| ALD | 110 (54.2) | 66 (52.4) | 44 (57.1) | .802 |
| Viral hepatitis | 50 (24.6) | 34 (27) | 16 (20.8) | |
| NASH | 15 (7.4) | 9 (7.1) | 6 (7.8) | |
| Other | 28 (13.8) | 17 (13.5) | 11 (14.3) | |
| BMI (kg/m2), median (IQR) | 24.6 (22.4‐28.0) | 25.8 (23.1‐28.5) | 24.0 (21.3‐27.0) | .004 |
| BMI strata, n (%) | ||||
| <25 kg/m2 | 105 (51.7) | 54 (42.9) | 51 (66.2) | .005 |
| 25‐30 kg/m2 | 65 (32) | 47 (37.3) | 18 (23.4) | |
| >30 kg/m2 | 33 (16.3) | 25 (19.8) | 8 (10.4) | |
| HVPG (mm Hg), median (IQR) | 19 (16‐23) | 20 (16‐23) | 18 (16‐22.5) | .211 |
| HVPG strata, n (%) | ||||
| HVPG 10‐19 mm Hg | 105 (51.7) | 61 (48.4) | 44 (57.1) | |
| HVPG ≥ 20 mm Hg | 98 (48.3) | 65 (51.6) | 33 (42.9) | |
| Ascites, n (%) | ||||
| Moderate ascites | 76 (37.4) | 52 (41.3) | 24 (31.2) | .001 |
| Severe ascites | 56 (27.6) | 23 (18.3) | 33 (42.9) | |
| Hepatic encephalopathy, n (%) | ||||
| No | 144 (70.9) | 91 (72.2) | 53 (68.8) | .606 |
| Yes | 59 (29.1) | 35 (27.8) | 24 (31.2) | |
| Presence of oesophageal varices, n(%) a | 178 (89.4) | 114 (91.2) | 64 (86.5) | .296 |
| Previous variceal bleeding, n (%) | 56 (27.6) | 39 (31.0) | 17 (22.1) | .175 |
| Use of NSBB for bleeding prophylaxis, n (%) b | 166 (81.8) | 109 (86.5) | 57 (74.0) | .025 |
| Compensated, n (%) | 54 (26.6) | 41 (32.5) | 13 (16.9) | .014 |
| Decompensated, n (%) | 149 (73.4) | 85 (67.5) | 64 (83.1) | |
| MELD, median (IQR) | 12 (9‐15) | 11 (9‐15) | 13 (10‐17) | .067 |
| Albumin (g/L), mean ± SD | 33.2 ± 5.7 | 33.4 ± 5.8 | 32.8 ± 5.5 | .465 |
| Creatinine (mg/dL), median (IQR) | 0.80 (0.66‐0.99) | 0.81 (0.68‐0.95) | 0.79 (0.62‐1.02) | .803 |
| Sodium (mmol/L), median (IQR) | 137 (134‐140) | 137 (135‐140) | 136 (133‐139) | .035 |
| Bilirubin (mg/dL), median (IQR) | 1.66 (0.97‐2.98) | 1.55 (0.95‐2.62) | 1.76 (1.08‐3.94) | .212 |
| INR | 1.3 (1.2‐1.4) | 1.3 (1.2‐1.4) | 1.3 (1.2‐1.5) | .269 |
a
Information on the presence of varices is not available in n = 4 patients.
b
Defined as initiation or ongoing use of NSBB therapy after/during baseline HVPG measurement.